LARVOL, a providesr of SaaS solutions to support the data and intelligence needs of the pharmaceutical and biotech industry, announced on Tuesday that it has appointed Mark Lagunowich as vice president, Global Sales.
With more that 30 years of experience in the life science industry, Lagunowich most recently led the Americas Life Science Sales Team for Clarivate Analytics.
Previously, Lagunowich worked as Global VP of Sales at Sparta Systems for eight years, selling a wide variety of business solutions to pharmaceutical, medical device, and clinical research (CRO) companies.
Lagunowich's appointment adds to several important new hires for LARVOL, including HR and Marketing leadership roles, as the company prepares to launch additional oncology-focused solutions in 2021. These include VIEW, a social listening platform aimed at capturing the conversations of oncology opinion leaders on Twitter, which will launch at ScaleUp 360 in April, along with CLIN, a complete database of immuno-oncology clinical trial data that will also launch in spring this year.
RedHill Biopharma reports positive opaganib data in venetoclax-resistant CLL
Vanda files FDA Biologics License Application for imsidolimab in generalized pustular psoriasis
Amferia raises EUR3.5m to advance antimicrobial wound-care platform
Sobi s Aspaveli marketing authorisation receives positive European regulatory opinion
Amgen's UPLIZNA receives US FDA approval
Innovent Biologics' mazdutide injection meets Phase 1b clinical study primary endpoint
FDA grants priority review to Bristol Myers Squibb's Opdivo regimen for advanced Hodgkin lymphoma
Physiomics secures new contract with Numab Therapeutics for preclinical antibody development
OTR Therapeutics agrees strategic collaboration and licence agreement with Zealand Pharma A/S
Privo Technologies doses first patient in first-in-human clinical trial of PRV131
Senhwa Biosciences signs clinical supply agreement with BeOne Medicines
InduPro secures strategic investment and collaboration with Sanofi to advance autoimmune therapy
Innovent Biologics reports first participant dosed in Phase 1 trial of IBI3011